Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has expanded its operational footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to the hub of biotechnology and pharmaceutical innovation in the Boston area, facilitating stronger partnerships and providing enhanced support for clinical trials throughout the region. The new office is set to bolster IAG’s comprehensive work across various therapeutic fields, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic, and metabolic diseases.
The establishment of the Cambridge office will enable IAG to collaborate more effectively with sponsors and contract research organizations engaged in Phase I-III clinical trials and imaging-intensive development programs. Additionally, this expansion is expected to create local employment opportunities, with plans to hire in areas such as clinical imaging operations, data science, regulatory support, and business development over the next 12 to 24 months. By offering end-to-end imaging services, IAG aims to enhance clinical trial design consultation, optimize imaging protocols, and ensure centralized image analysis and regulatory-compliant data delivery.
IAG’s presence in the Boston life-sciences ecosystem is poised to improve collaboration with key stakeholders, including biotechnology companies, pharmaceutical organizations, academic institutions, and clinical research centers. This move aligns with the company’s global operations strategy, which supports clinical trials across North America, Europe, and the Asia-Pacific region. IAG’s standardized imaging protocols and centralized data harmonization are designed to provide consistent imaging analysis across international trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO), offering support to pharmaceutical, biotechnology, and medical technology companies in conducting imaging-based clinical trial endpoints. IAG’s expertise spans multiple areas such as oncology, inflammatory diseases, musculoskeletal, cardiometabolic, and rare disease indications. The company’s DYNAMIKA™ platform integrates AI-driven image analysis with centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight.
For more information about Image Analysis Group, interested parties can visit their website at www.ia-grp.com or contact them via email at [email protected]. To reach the press contact, Marie Fussell, inquiries can be made by phone at +1 267-857-8638 or via email at [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.